Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Phase I study of the ATR inhibitor M1774 in patients with solid tumors

Timothy Yap • 10 Sep 2022
ESMO 2022
M1744 Niraparib

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX discusses the A1 results from the Phase I study of M1744 (NCT04170153), a potent, selective, orally administered ATR inhibitor that exerts antitumor activity in preclinical models. These early data show M1774 monotherapy in patients with advanced solid tumors is well-tolerated, and M1774 is under continued investigation in a biomarker-selected population in combination with niraparib. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

More from Timothy Yap

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:41
Copanlisib and olaparib in PIK3CA hotspot, PTEN and DDR mutant tumors
Timothy Yap • 7 Apr 2024
2:31
PF-07220060 in HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy
Timothy Yap • 2 Jun 2023
1:24
A phase I/II trial to preliminary efficacy of BNT142 in prospectively confirmed CLDN6+ solid tumors
Timothy Yap • 2 Jun 2023
The content of VJOncology is intended for healthcare professionals